2 7 treatment Zenkuda in Diabetic Retinopathy: A durable anti-VEGF therapy could expand treatment in DR • While higher than previously estimated, use remains low • DR is often asymptomatic and approved therapies require frequent injections • These challenges contribute to today’s “watch-and-wait” approach ~9% treated with anti-VEGF therapy in 2025 1 ~9% Zenkuda’s 6-month dosing has the potential to expand anti-VEGF adoption Fewer injections with all patients on 6-month dosing at Year 1* 2 • Potential to increase patient compliance • May catalyze more at-risk patients to seek earlier treatment, given risk of disease progression A reduced treatment burden could catalyze the DR market Strong efficacy 2 • Superior ≥2-step improvement in DRSS • Reduced risk of developing sight-threatening complications by ≥85% *After initiation phase 1. Roche epidemiology data from 2025. 2. Based on the results from the GLOW1 and GLOW2 Phase 3 studies in DR.